Urokinase inhibitors, production and use thereof

Details Urokinase inhibitors, production and use thereof Urokinase inhibitors, production and use thereof

2003-03-11

2010-11-23

Zucker, Paul A (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C564S162000

Reexamination Certificate

active

07838560

ABSTRACT:
The invention relates to novel inhibitors of urokinase and to their preparation and use for the therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases.

REFERENCES:
patent: 5518735 (1996-05-01), Stürzebecher et al.
patent: 5602253 (1997-02-01), Antonsson et al.
patent: 5705487 (1998-01-01), Schacht et al.
patent: 5707966 (1998-01-01), Schacht et al.
patent: 5710130 (1998-01-01), Schacht et al.
patent: 5726159 (1998-03-01), Schacht et al.
patent: 5786328 (1998-07-01), Dennis et al.
patent: 5863929 (1999-01-01), Klimkowski et al.
patent: 5914319 (1999-06-01), Schacht et al.
patent: 6030972 (2000-02-01), Böhm et al.
patent: 6472393 (2002-10-01), Aliagas-Martin et al.
patent: 6586405 (2003-07-01), Semple et al.
patent: 6624169 (2003-09-01), Wilhelm et al.
patent: 6680320 (2004-01-01), Wilhelm et al.
patent: 6831196 (2004-12-01), Stürzebecher et al.
patent: 6841701 (2005-01-01), Stürzebecher et al.
patent: 6841702 (2005-01-01), Magdolen et al.
patent: 7038074 (2006-05-01), Moroder et al.
patent: 7049460 (2006-05-01), Magdolen et al.
patent: 7208521 (2007-04-01), Magdolen et al.
patent: 7342018 (2008-03-01), Wilhelm et al.
patent: 7407982 (2008-08-01), Steinmetzer et al.
patent: 7538216 (2009-05-01), Sperl
patent: 7608623 (2009-10-01), Sperl et al.
patent: 2004/0087511 (2004-05-01), Shiraishi et al.
patent: 2004/0266766 (2004-12-01), Sperl
patent: 2005/0119190 (2005-06-01), Stürzebecher et al.
patent: 2006/0068457 (2006-03-01), Ziegler et al.
patent: 2006/0148901 (2006-07-01), Stürzebecher et al.
patent: 2007/0055065 (2007-03-01), Stürzebecher et al.
patent: 2007/0066539 (2007-03-01), Stürzebecher et al.
patent: 2008/0261998 (2008-10-01), Sperl et al.
patent: 2009/0117185 (2009-05-01), Steinmetzer et al.
patent: 2010/0022781 (2010-01-01), Steinmetzer et al.
patent: 2412181 (2002-12-01), None
patent: 689 611 (1999-07-01), None
patent: 42 43 858 (1994-06-01), None
patent: 100 29 015 (2001-12-01), None
patent: 10029014 (2001-12-01), None
patent: 102 10 590 (2002-03-01), None
patent: 102 12 555 (2003-09-01), None
patent: 103 01 300 (2004-07-01), None
patent: 0 183 271 (1986-06-01), None
patent: 0 669 317 (1995-08-01), None
patent: 0 672 658 (1995-09-01), None
patent: 1 364 960 (2003-11-01), None
patent: WO 92/08709 (1992-05-01), None
patent: WO 94/18185 (1994-08-01), None
patent: WO 94/29336 (1994-12-01), None
patent: WO 95/17885 (1995-07-01), None
patent: WO 95/29189 (1995-11-01), None
patent: WO 96/25426 (1996-08-01), None
patent: WO 97/23499 (1997-07-01), None
patent: WO 99/05096 (1999-02-01), None
patent: WO 00/04954 (2000-02-01), None
patent: WO 00/05245 (2000-02-01), None
patent: WO 00/14110 (2000-03-01), None
patent: WO 00/17158 (2000-03-01), None
patent: WO 00/58346 (2000-10-01), None
patent: WO 00/64470 (2000-11-01), None
patent: WO 01/81314 (2001-11-01), None
patent: WO 01/96286 (2001-12-01), None
patent: WO 01/96366 (2001-12-01), None
patent: WO 01/97794 (2001-12-01), None
patent: WO 02/06280 (2002-01-01), None
patent: WO 02/14349 (2002-02-01), None
patent: WO 02/20475 (2002-03-01), None
patent: WO 02/50056 (2002-06-01), None
patent: WO 03/070229 (2003-08-01), None
patent: WO 2004/062657 (2004-07-01), None
Baker et al., “Inhibition of Cancer Cell Urokinase Plasminogen Activator by Its Specific Inhibitor PAI-2 and Subsequent Effects on Extracellular Matrix Degradation,”Cancer Research50:4676-4684 (1990).
Cajot et al., “Plasminogen-Activator Inhibitor Type 1 is a Potent Natural Inhibitor of Extracellular Matrix Degradation by Fibrosarcoma and Colon Carcinoma Cells,”Proc. Natl. Acad. Sci. USA87:6939-6943 (1990).
Dixon, “The Determination of Enzyme Inhibitor Constants,”Biochem. J.55:170-171 (1953).
Duggan et al., Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Breast Cancer,Int. J. Cancer61:597-600 (1995).
Judkins et al., “A Versatile Synthesis of Amidines from Nitriles Via Amidoximes,”Synthetic Communications26:4351-4367 (1996).
Kettner et al., “Inactivation of Trypsin-Like Enzymes with Peptides of Arginine Chloromethyl Ketone,”Methods in Enzymology80:826-843 (1981).
Krüger et al., “Host TIMP-1 Overexpression Confers Resistance to Experimental Brain Metastasis of a Fibrosarcoma Cell Line,”Oncogene16:2419-2423 (1998).
Krüger et al., “The BacterialLacZGene: An Important Tool for Metastasis Research and Evaluation of New Cancer Therapies,”Cancer and Metastasis Reviews17:285-294 (1999).
Künzel et al., “4-Amidinobenzylamine-Based Inhibitors of Urokinase,”Biorganic&Medicinal Chemistry Letters12:645-648 (2002).
Mignatti et al., “Biology and Biochemistry of Proteinases in Tumor Invasion,”Physiological Reviews73:161-195 (1993).
Ossowski et al., “Antibodies to Plasminogen Activator Inhibit Human Tumor Metastasis,” Cell 35:611-619 (1983).
Pedersen et al., “Prognostic Impact of Urokinase, Urokinase Receptor, and Type 1 Plasminogen Activator Inhibitor in Squamous and Large Cell Lung Cancer Tissue,” Cancer Research 54:4671-4675 (1994).
Reuning et al., “Multifunctional Potential of the Plasminogen Activation System in Tumor Invasion and Metastasis (Review),”International Journal of Oncology13:893-906 (1998).
Schechter et al., “On the Size of the Active Site in Proteases,”Biochemical and Biophysical Research Communications, 27:157-162 (1967).
Schmitt et al., “Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy,”Thrombosis and Haemostasis78:285-296 (1997).
Sperl et al., “(4-Aminomethyl) Phenylguanidine Derivates as Nonpeptidic Highly Selective Inhibitors of Human Urokinase,”PNAS97:5113-5118 (2000).
Stephens et al., “The Urokinase Plasminogen Activator System as a Target for Prognostic Studies in Breast Cancer,”Breast Cancer Research and Treatment, 52:99-111 (1998).
Stürzebecher et al., “3-Amidinophenylalanine-Based Inhibitors of Urokinase,”Bioorganic&Medicinal Chemistry Letters9:3147-3152 (1999).
Stürzebecher et al., “Synthesis and Structure -Activity Relationships of Potent Thrombin Inhibitors: Piperazides of 3-Amidinophenylalanine,”J. Med. Chem.40:3091-3099 (1997).
Stürzebecher et al., “Synthetische Inhibitoren der Serinproteinasen,”Pharmazie33:599-602 (1978).
Sucker et al., “Pharm. Techn. 2.,” Bauer, Georg Thieme Verlag, Stuttgart, 1991.
Tamura et al., “Synthesis and Biological Activity of Peptidyl Aldehyde Urokinase Inhibitors,”Bioorganic&Medicinal Chemistry Letters10:983-987 (2000).
Towle et al., “Inhibition of Urokinase by 4-Substituted Benzo[b]thiophene-2-Carboxamidines: An Important New Class of Selective Synthetic Urokinase Inhibitor,”Cancer Research53:2553-2559 (1993).
Vassalli et al., “Amiloride Selectively Inhibits the Urokinase-Type Plasminogen Activator,”FEB214:187-191 (1987).
Zeslawska et al., “Crystals of Urokinase Type Plasminogen Activator Complexes Reveal the Binding Mode of Peptidomimetic Inhibitors,”J. Mol.Biol.328:109-118 (2003).
Akers, “Excipient-Drug Interactions in Parenteral Formulations.”J. Pharm. Sci.91(11):2283-2300 (2002).
Asghar et al., “Human Plasma Kallikreins and Their Inhibition by Amidino Compounds,”Biochim. Biophys. Acta438:250-264 (1976).
Bauer, “Hilfsstoffe,” inPharmazeutische Technologie. Sucker et al. (eds.), Georg Thieme Verlag Stuttgart: New York, p. 174-216 (1991).
Bookser et al., “Syntheses of Quadruply Two-and Three-Atom, Aza-Bridged, Cofacial Bis (5,10,15,20-Tetraphenylporphyrins),”J. Am. Chem. Soc.113:4208-4218 (1991).
Choi-Sledeski et al., “Discovery of an Orally Efficacious Inhibitor of Coagulation Factor Xa Which Incorporates a Neutral P1Ligand,”J. Med. Chem.46:681-684 (2003).
Collen et al., “In

Affiliated with

Also associated with

Rating

Urokinase inhibitors, production and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Urokinase inhibitors, production and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urokinase inhibitors, production and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4237552